EGFR and non-small cell lung carcinoma: It was previously shown that NSCLC patients who had specific EGFR gene mutations, especially in-frame deletions in exon 19 (ΔLRE) and a point mutation in exon 21 (L858R), could benefit from gefitinib (17).